Skip to main content

Table 2 Synergistic range in different pancreatic cancer cell lines with varying genetic status

From: Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

 

AsPC-1

BxPc-3

Capan-1

MIA PaCa-2

PANC-1

K-ras

mut

wt

mut

mut

mut

p53

nk

mut

mut

mut

mut

p16

nk

-

-

-

-

P276-00

R

R

R

MS

MS

Gemcitabine

MS

S

R

R

MS

G + P276-00 (CI)

MSy

HSy

WSy

MSy

MSy

 

(0.86-0.89)

(0.38-0.69)

(0.9-0.93)

(0.71-0.95)

(0.6-0.72)

  1. nk: not known -: deletion mut: mutated wt: wild type.
  2. S: sensitive MS: moderately sensitive R: resistant.
  3. WSy: weakly synergistic MSy: moderately synergistic HSy: highly synergistic.